Table 3.
Treatment Group | Viability |
---|---|
rhBMP-2 | 96% |
scAAV-equine-BMP-2 | 97% |
scAAV-GFP | 99% |
Osteogenic Control | 99% |
Negative Control | 99% |
Treatment Group | Viability |
---|---|
rhBMP-2 | 96% |
scAAV-equine-BMP-2 | 97% |
scAAV-GFP | 99% |
Osteogenic Control | 99% |
Negative Control | 99% |